Biotech and Pharmaceuticals Pharmaceuticals

  • Scientist working in lab

    Politicians want to cut drug prices, but they face a wall of conflicts, including their own.

  • Jeff Abraham

    Promescent CEO Jeff Abraham details the company's lawsuit against consumer giant Reckitt Benckiser for $150 million, alleging fraud and theft of trade secrets.

  • March 22- Allergan Plc on Friday agreed to split its chairman and chief executive roles, but only at its next leadership change, as the drugmaker pushed back against claims from activist hedge fund Appaloosa LP that an independent chair could help current CEO Brent Saunders boost the company's sagging share price. The Botox maker announced the change in its...

  • March 22- Allergan Plc plans to elect an independent board chairman, starting with the next leadership transition, the Botox maker said on Friday, as the drugmaker responds to calls from hedge fund Appaloosa LP to separate the roles of chairman and chief executive officer. Appaloosa, led by billionaire David Tepper, has been pressing Allergan since last year to...

  • LOUISVILLE, Ky., March 22- United Parcel Service Inc wants to get beyond U.S. doorsteps with a new push into healthcare. Deutsche Post's DHL Group dominates the market, which is expected to grow to $105 billion by 2021.. "Over-the-threshold services is where the world is headed," Chris Cassidy, who joined UPS last year from GlaxoSmithKline PLC to oversee global...

  • Amyloid plaques accumulate outside neurons. Amyloid plaques are characteristic features of Alzheimer's disease. They lead to a degeneration of the affected neurons.

    Eisai said it has begun phase 3 clinical trials of Alzheimer's treatment, a day after the Japanese drugmaker and U.S. partner Biogen scrapped trials for its own Alzheimer's drug.

  • *Eisai tumbles to daily limit-low. TOKYO, March 22- Japan's Nikkei ended little changed on Friday as chip-related stocks offset weakness in financial stocks and drugmakers, which tumbled after Eisai said it will end its Alzheimer drug trials. But financial stocks sold off after the spread between the three-month Treasury bill yield and the 10- year note yield...

  • TOKYO, March 22- Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab. The demise of aducanumab came after independent experts determined the trials had little hope of succeeding, marking the...

  • LOUISVILLE, Ky., March 22- United Parcel Service Inc wants to get beyond U.S. doorsteps with a new push into healthcare. Deutsche Post's DHL Group dominates the market, which is expected to grow to $105 billion by 2021.. "Over-the-threshold services is where the world is headed," Chris Cassidy, who joined UPS last year from GlaxoSmithKline PLC to oversee global...

  • biotech

    Charley Grant, Wall Street Journal, joins 'The Exchange' to discuss the fall of Biogen's stock after the company announced it would end trials for its experimental Alzheimer's drug.

  • CHICAGO/ TOKYO, March 21- Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and blow to Biogen, which lost more than $18 billion of its value on Thursday. The announcement took a punishing toll on Biogen, whose...

  • 30mg tablets of Shire Plc's Adderall XR.

    Certain medications commonly used to treat ADHD in teens and young adults may increase their risk of psychosis, according to researchers at Harvard Medical School and McLean Hospital.

  • Since last summer, the FDA has been conducting a major investigation to address the presence of certain impurities in a class of drugs called angiotensin II receptor blockers, including losartan. Last week, the FDA approved a new generic version of valsartan to ease the shortages triggered by several manufacturers recalling the drug over possible cancer...

  • Ro, the men's health start-up known for straight-to-your-door erectile dysfunction medication, is launching a new service targeting women.

  • (L-R) Richard A. Gonzalez, chairman and CEO of AbbVie Inc., Pascal Soriot, executive director and CEO of AstraZeneca, Giovanni Caforio, chairman of the board and CEO of Bristol-Myers Squibb Co., Jennifer Taubert, executive vice president and worldwide chairman of Janssen Pharmaceuticals, Johnson & Johnson, Kenneth C. Frazier, chairman and CEO of Merck & Co. Inc., Albert Bourla, CEO of Pfizer, and Olivier Brandicourt, CEO of Sanofi testify in front of the Senate Finance Committee on 'Drug Pricing in America: A Prescription for Change, Part II' on February 26, 2019 in the Dirksen Senate Office Building in Washington, DC.

    Pfizer Inc said on Wednesday it has acquired a 15 percent stake in Vivet Therapeutics, and has an exclusive option to fully acquire the privately held French company that develops gene therapies for liver disorders.

  • OTTAWA, March 19- Canada will create a national drug agency to help cut the cost of prescription medications as part of a plan to broaden the state-funded healthcare program, the finance ministry said in its budget on Tuesday. Prescription drug spending in Canada has jumped to C $33.7 billion in 2018 from C $2.6 billion in 1985 and a promise to boost drug coverage...

  • A U.S. jury on Tuesday found Bayer AG's glyphosate-based weed killer to be a "substantial factor" in causing a man's non-Hodgkin's lymphoma, allowing the trial to proceed into a second phase on liability and damages.

  • Wellington Management Company LLP's decision last month to speak out against drug maker Bristol-Myers Squibb Co's proposed $74 billion acquisition of Celgene Corp, calling what would be the largest-ever pharmaceutical takeover too risky and expensive, sent ripples across the investment world. This is because these tactics have typically been the...

  • ZURICH, March 14- Novartis's generics chief is quitting after the Swiss drugmaker sold parts of the business and initiated an 18- month revamp, fueling speculation about an eventual spin-off or sale. Richard Francis, Sandoz's boss since 2014, is stepping down, Novartis Chief Executive Vas Narasimhan said on Thursday, adding "Richard has decided that for...

  • March 13- Purdue Pharma's Chief Executive Officer Craig Landau said the company is considering bankruptcy, the Washington Post reported on Wednesday, as the OxyContin maker faces a slew of lawsuits alleging the drugmaker contributed to opioid epidemic sweeping the United States. Filing for Chapter 11 protection would halt the lawsuits and allow Purdue to...